News
pharmaphorum speaks with Steven Davis of AstraZeneca on how the first year of its first direct-to-patient program - ARIMIDEX Direct has been. A year ago, AstraZeneca announced its first direct-to ...
The UK pharma has already sold rights to both Arimidex and Casodex in the US in 2017. There were no closing conditions to the divestment and the agreement became effective on signing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback